Intensity Therapeutics raises $11.3M, extends cash runway to H2 2026; Q2 net loss narrows to $2.5M

INTENSITY THERAPEUTICS, INC.

2025-Q2 EPS reported -$0.35

Net proceeds of ~$10.1M from two public offerings and ATM; cash runway now into H2 2026.
Q2 2025 net loss $2.5M vs $5.0M in Q2 2024; R&D expense fell to $1.5M from $3.6M.
INVINCIBLE-3 (soft tissue sarcoma) enrollment paused in March after 23 patients; existing patients continue dosing.
INVINCIBLE-4 (triple-negative breast cancer) recruiting in France and Switzerland; EMA authorized initiation.
INT230-6 showed 100% complete response in preclinical MPNST models; company believes Nasdaq compliance restored.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.